LGI1 Antibody
| Code | Size | Price |
|---|
| PSI-4531-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-4531-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Western Blot (WB)
Documents
Further Information
Additional Names:
LGI1 Antibody: EPT, ETL1, ADLTE, ADPAEF, ADPEAF, IB1099, EPITEMPIN, EPT, UNQ775/PRO1569, Leucine-rich glioma-inactivated protein 1, Epitempin-1
Application Note:
LGI1 antibody can be used for the detection of LGI1 by Western blot at 1 μg/mL.
Antibody validated: Western Blot in mouse samples. All other applications and species not yet tested.
Antibody validated: Western Blot in mouse samples. All other applications and species not yet tested.
Background:
LGI1 Antibody: The leucine-rich, glioma inactivated gene 1 (LGI1) was first identified as a candidate tumor suppressor gene for glioma and may play a role in other cancers. LGI1 is a member of a family of highly related proteins containing leucine-rich repeats (LRRs) which are highly similar to other transmembrane signaling molecules and receptors. LGI1 serves as a ligand to ADAM22, a metalloprotease localized at the synapse. Mutations in LGI1 account for nearly half of autodominant lateral temporal epilepsy (ADTLE), an epileptic syndrome characterized by focal seizures with predominant auditory symptoms. Two isoforms of LGI1 are known to exist, but the top band seen in the western blot is likely to be non-specific. This LGI1 antibody is predicted to be specific to LGI1 and not recognize other LGI proteins.
Background References:
- Chernova OB, Somerville RP and Cowell JK. A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors. Oncogene1998; 17:2873-81.
- Fialka F, Gruber RM, Hitt R, et al. CPA6, FMO2, LGI1, SIAT1 and TNC are differentially expressed in early- and late-stage oral squamous cell carcinoma - A pilot study. Oral Oncol.2008;
- Gu W, Gibert Y, Wirth T, et al. Using gene-history and expression analysis to assess the involvement of LGI genes in human disorders. Mol. Biol. Evol.2005; 22:2209-16.
- Fukata Y, Adesnik H, Iwanaga T, et al. Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate synaptic transmission. Science2006; 313:1792-5.
Buffer:
LGI1 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Bovine: (100%)
Immunogen:
LGI1 antibody was raised against a 13 amino acid synthetic peptide from near the amino terminus of human LGI1.
The immunogen is located within the first 50 amino acids of LGI1.
The immunogen is located within the first 50 amino acids of LGI1.
NCBI Gene ID #:
9211
NCBI Official Name:
leucine-rich, glioma inactivated 1
NCBI Official Symbol:
LGI1
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
AAQ89244
Protein GI Number:
37182888
Purification:
LGI1 Antibody is affinity chromatography purified via peptide column.
Research Area:
Neuroscience,Cancer
Swissprot #:
O95970
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | LGI1 Peptide | PSI-4531P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|